Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Are novel immunotherapeutics and targeted treatments going to transform the management of CRC? 

Neoadjuvant immunotherapy in CRC: where do we go from here?

Date

09 Sep 2022

Session

Are novel immunotherapeutics and targeted treatments going to transform the management of CRC? 

Topics

Cancer Biology;  Translational Research;  Immunotherapy

Tumour Site

Colon and Rectal Cancer

Presenters

Myriam Chalabi

Authors

M. Chalabi

Author affiliations

  • Gastrointestinal Oncology Dept, Netherlands Cancer Institute, 1006 BE - Amsterdam/NL
More

Resources

Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.